GE HealthCare
  1. Companies
  2. GE HealthCare
  3. Products
  4. GE HealthCare - Model Invenia ABUS 2.0 ...

GE HealthCareModel Invenia ABUS 2.0 - Breast Ultrasound Solutions & Systems

SHARE
The Invenia ABUS 2.0 is designed as an FDA-approved ultrasound supplemental screening technology, aiming to improve cancer detection in women with dense breast tissue. It offers a 35.7% increase in detection over traditional mammography, thanks to its superior image quality and advanced interpretation tools. The system integrates AI assistance to enhance clinical confidence by detecting and characterizing breast lesions, thus aiding healthcare practitioners in identifying small, invasive cancers that might go unnoticed with conventional imaging. Additionally, the system is built for user-friendly operations, allowing for comprehensive lesion assessment through labeling, measuring, and comparison tools, including 2D shear wave elastography for tissue elasticity assessment. The Invenia ABUS 2.0 stands as an imperative tool in providing personalized and comprehensive breast cancer screening and diagnosis.
Most popular related searches

Clinical evidence is growing about the effectiveness of ultrasound for finding small, node-negative, invasive cancers that may be missed by mammography1. Patient-friendly Invenia™ ABUS 2.0 is the first FDA-approved ultrasound supplemental screening technology that is specifically designed for detecting cancer in dense breast tissue.

 

Designed for screening

Improve breast cancer detection by 35.7 percent over mammography alone.2

 

Remarkable image quality

Look differently at dense breast tissue with advanced interpretation tools

 

AI Assistant

Helps to detect and characterize breast lesions for clinical confidence

Screening; diagnosis and staging; treatment; and follow-up: Our breast ultrasound offerings feature excellent measurement and decision support tools to help you provide excellent care for your patients wherever they may be on the care pathway.